Monday, November 23, 2015 9:25:46 AM
1) ELITE is about to put out the BIGGEST PR in the company's history in JANUARY or sooner.
2) ELITE is scaling up a SECOND manufacturing line and installed a VAULT to store ELI 200.
This means Elite is capable of launching ELI 200 with its current equipment PLUS a few additional ADT products! PLUS Nasrat plans to file 2 additional NDAs in 2016.
We have installed a second packaging line and we are very close to finishing the construction so we can start the validation and scale up activity. A small note on that. [color=red]The current equipment we have our [GLAS60] would be capable of launching initially ELI-200. Once we activate the new facility then we will have the capability to launch multiple products.[/color]
3) ELITE plans on expanding and beefing up its GENERIC pipeline!!
Elite is currently Cash Flow Positive (CFP) on its operations minus R&D costs and cutting into those R&D costs slowly and surely quarter by quarter! Nasrat stated previously he would go out and buy additional ANDAs worth way more than the existing generic products.
4) 5 states already passed laws to REQUIRE insurance companies to pay for Abuse Deterrent Opioids. Florida and Ohio could be next as the powers that be are pushing to pass ADT laws in most states.
1) Colorado
2) Utah
3) Maine
4) Maryland
5) Massachusetts
http://abusedeterrent.org/news/Portman-Calls-on-Administration-to-Halt-Harmful-Opioid-Rule.aspx#.VlGpAng3-FI
5) Even with existing pressure on lawmakers to pass abuse deterrent opioid laws, Medicare is showing that it still prefers to pay for cheaper generic non ADT opioids and will do so until forced otherwise.
http://khn.org/news/medicare-drug-plans-favor-generic-opioids-over-those-designed-to-avoid-abuse-study-finds/?utm_campaign=KHN%3A+First+Edition&utm_source=hs_email&utm_medium=email&utm_content=18294693&_hsenc=p2ANqtz-83L8HtGq_OQ-mrezx46wvS6SkU0JKQgFVptr05XwnylCv5_y4RfdVdC-bAopFmm0hNVw9GZKlpHKxTfEeWHpXIv3mbAQ&_hsmi=18294693
Elite has an answer for this problem as well! It's called ELI 300 and ELI 301. Elite's 2 generic ADT opioids.
http://www.elitepharma.com/pipeline-generics/
6) Once the various states insurance covers abuse deterrent opioids and ELI 200 gets approved, here is EXACTLY why Elite will steal HUGE revenues from the competition. Physicians like Elite's ADT best.
http://www.fiercedrugdelivery.com/story/physicians-call-novel-abuse-deterrent-opioid-agonistantagonist-formulations/2015-11-09
A survey of more than 200 physicians found that 31% think opioid antagonists is the abuse-deterrent formulation that is most needed to combat the opioid abuse epidemic--an issue that's been implicated in the startling rise of the death rate of middle-aged white Americans without a college degree.
What type of abuse- deterrent formulation is most needed?
Number (out of 214 respondents)
Opioid antagonist/agonist combination 66 (31%)
Physical or chemical barrier 48 (22%)
Novel delivery system 34 (16%)
Aversion 33 (15%)
Prodrug 14 (7%)
Other or combination of above 19 (9%)
FierceDrugDelivery supplied the question to Quantia MD, the provider of a physician engagement platform that counts one-third of U.S. doctors as its members.
Out of 214 physicians, 66 said opioid antagonists/agonists are the most needed formulation. Opioid antagonists are substances that interfere with the euphoria associated with drug abuse. The deterrents would generally be released and activated only if the product is manipulated, such as during crushing or snorting.
7) Should Elite's ADT prove to be highly effective there is a chance that the FDA would pull all other non ADT opioids off the market in that particular opioid class. Notice from the article link provided below there is considerable pressure being placed on the FDA to follow through on this very possibility.
http://raps.org/Regulatory-Focus/News/2015/01/20/21120/Should-FDA-Pull-Non-Abuse-Deterrent-Generic-Opioids-off-the-Market-PhRMA-Bio-Say-Yes/
8) The global market for pain management is growing exponentially and currently sits around $60 billion. Further, the largest segment of this financially is the pharmaceutical industry. Given the aging of our population this number will only continue to grow year after year.
http://www.prweb.com/releases/2011/1/prweb8052240.htm
9) Elite has very similar abuse deterrent technology (ADT) to Pfizer who is the Market Leader in Global Pain Treatment. As Nasrat has said let Pfizer educate the doctors, insurance companies and the public at large about their ADT opioids and Elite will ride their coattails.
http://www.fiercebiotech.com/press-releases/pfizer-market-leader-global-pain-treatment-market-companiesandmarketscom
Further, when the likes of Pfizer and Purdue begin paying to conduct research and public educational studies related to ADT opioids one knows ADTs are the wave of the future.
http://avalere.com/expertise/managed-care/insights/medicare-drug-plans-favor-generic-opioids-that-lack-abuse-deterrent-propert
http://www.teamagainstopioidabuse.com
10) *****My Personal Favorite is Elite will IMO be partnering with a BP for ELI 216 and that whoever this company is stands a SOLID chance of BUYING ELTP out altogether in 2017.
Fear Uncertainty and Doubt FUD It Ain't Going To Work Here Anymore. Notice the lack of question mark.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 08:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 09:30:05 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/31/2023 08:20:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2023 08:15:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/29/2023 09:15:09 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/29/2023 08:43:45 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM